Back to blog
Salt Lake City - Echelon Biosciences, Inc. (EBI) announces the acquisition of California Peptide Research, Inc. (CPRI) to offer its line of biochemicals and research peptides, and to further drive innovations in the growing peptide research and development markets.
The primary customers of EBI include pharmaceutical and research and development companies, whose research indicates dramatic growth in the peptide therapeutics market and vast expansion over the next five years.
"The acquisition represents a natural, strategic step for Echelon," said W. Tim Miller, President and CEO of EBI.
According to a report published Mar. 13, 2013 by Transparency Market Research, "...the global peptide therapeutics market was valued at USD 14.1 billion in 2011 and is estimated to reach a market worth USD 25.4 billion in 2018..."
"Peptide therapeutics show neurological applications, including Alzheimer's disease," said Miller, "Along with broader capabilities for developing assays - superior to traditional methods."
CPRI was founded in 1993, and remains a recognized provider of standard, unique and custom peptides for use in medical research, biology and biochemistry, continually maintaining a reputation for reliable and quality products in the peptide research field.
"This will provide Echelon an expanded offering of research reagents to our pharmaceutical and diagnostic customers," said Miller, "As well as incorporate the peptide expertise into our own research and development."
CPRI will relocate operations to the Salt Lake City-based facility of EBI, and join corporate divisions that include Logan, UT-based Frontier Specialty Chemicals, Inc.
CPRI products will continue to be offered via the CPRI website, additionally via the EBI website
"We are please to have completed the acquisition of California Peptide," said Miller, "This acquisition allows Echelon to marry its strength, credibility and biochemical research expertise with the service and product offerings of CPRI."
0.2
/ 0.3
Related Articles
Stay informed with our informative blog posts.
Echelon joins NIH Common Fund Resources List
Echelon Biosciences Inc. is pleased to join the NIH Glycoscience Common Fund Program listing of Companies w/ Glycoscience Catalogs
Echelon Biosciences participates at Life Sciences Day with BioUtah
Utah’s flourishing Life Sciences Industry was proudly on display at the 2023 Annual Life Sciences Day on Capitol Hill. Echelon B
Echelon Biosciences announces partnership with ProBioscience Technologies for distribution in Southeast Asia
Echelon Biosciences Inc. (EBI) is excited to announce a new partnership with ProBioscience Technologies for product distribution i
Echelon Biosciences selected as the 2022 Bioz “Rising Star” ELISA Winner
November, 15, 2022 – Salt Lake City, UT, USA – Echelon Biosciences announces that it has been selected as the 2022 Bioz S
25 Years of Supporting Science
This year marks a major milestone for Echelon Biosciences (EBI). We are celebrating our 25th Anniversary as a company. EBI’s
HTL Biotechnology and Echelon Biosciences Inc. announce strategic partnership
(Salt Lake City, UT and Paris, FR, April 13, 2021) – HTL, the worldwide leader in biotechnology solutions using hyaluronic acid
0.3
/ 0.3
Get in Touch
If you have any questions or would like to learn more about our services, feel free to reach out to us. We’re here to help!
Biosciences